To the Editor.—
At the Washington (DC) Hospital Center, seven psoriatic patients who were unresponsive to three weeks of intensive inpatient Goeckerman therapy—ultraviolet-B radiation (UV-B) twice daily and a topical application of tar—have, over the years, been treated with combined therapy, including the combinations of Goeckerman therapy with psoralens and ultraviolet-A (PUVA), with methotrexate, with hydroxyurea (Hydrea), with both PUVA and methotrexate, and with both PUVA and hydroxyurea.Hydroxyurea, an S-phase mitotic inhibitor, has been used with benefit in psoriasis.1,2 We have used this agent in combination with UV-B and/or PUVA in five patients. We have observed three patients in whom the combination of hydroxyurea with UV-B was associated with a characteristic pain in psoriatic lesions, which to our knowledge has not previously been described. This pain begins during UV-B therapy and lasts for one to three hours. We herein present three case reports.
Report of Cases.—Case 1.—
Sparks MK, Moshell AN, Nigra TP. Hydroxyurea and Pain in Psoriatic Lesions During Ultraviolet-B Radiation. Arch Dermatol. 1985;121(9):1107. doi:10.1001/archderm.1985.01660090021006
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.